Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients.

Clinical chemistry and laboratory medicine - 28 Jul 2020

Macías Mónica, Cañada-Higueras Eva, Alegre Estibaliz, Bielsa Arancha, Gracia Javier, Patiño-García Ana, Ferrer-Costa Roser, Sendino Teresa, Andueza María P, Mateos Beatriz, Rodríguez Javier, Corral Jesús, Gúrpide Alfonso, Lopez-Picazo José M, Perez-Gracia Jose L, Gil-Bazo Ignacio, Alkorta-Aranburu Gorka, González Álvaro

Abstract excerpt

Background Genomic alterations studies in cell-free DNA (cfDNA) have increasing clinical use in oncology. Next-generation sequencing (NGS) technology provides the most complete mutational analysis, but nowadays limited data are available related to the comparison of results reported by different platforms. Here we compare two NGS panels for cfDNA: Oncomine™ Pan-Cancer Cell-Free Assay (Thermo Fisher Scientific),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 32623849
DOI: 10.1515/cclm-2019-1267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients.PMID 32623849Read ↗

Baseline mutation profiling of 1134 samples of circulating cell-free DNA and blood cells from healthy individualsSemantic proximity Read ↗

A panel sequencing dataset of peripheral blood gene variations in pan-cancer.Semantic proximity Read ↗

Strategies for improving detection of circulating tumor DNA using next generation sequencing.Semantic proximity Read ↗

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring.Semantic proximity Read ↗

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read ↗

Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.Semantic proximity Read ↗

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read ↗

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA SequencingSemantic proximity Read ↗

Cell-Free DNA, Tumor Molecular Concordance, and Clinical Correlates of Patients with Cancer Treated in a Large Community Health Care NetworkSemantic proximity Read ↗

Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.Semantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.